We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis

By LabMedica International staff writers
Posted on 11 Jun 2024
Print article
Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)
Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)

To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood proteins can influence cancer risk, highlighting the need for further investigation to determine which proteins could be effectively utilized for prevention. Researchers have now employed a cutting-edge proteomics platform to identify blood proteins that could potentially provide a seven-year advance warning for various types of cancer. Their study findings underscore the significant potential of proteomics to transform cancer detection, enabling earlier interventions that could lead to improved treatment success and possibly even prevention.

In this groundbreaking study recently published in Nature Communications, the researchers used Olink Holding AB’s (Uppsala, Sweden) next-generation Olink Explore proteomics platform to examine blood samples from over 44,000 individuals. They successfully identified 371 proteins associated with 19 different types of cancer, including 107 proteins that could be detected in individuals up to seven years before a cancer diagnosis was made. The platform's scalability and precision allowed the researchers to conduct detailed analyses of a vast array of proteins across a large number of samples, revealing vital insights into the complex protein dynamics of the human body. Although these results are highly promising for the advancement of cancer management, the researchers have stressed the importance of further studies. It is essential to delve deeper into the roles these proteins play in the onset of cancer and to identify the most dependable proteins for future diagnostic tests.

“This breakthrough research, enabled by the Olink platform and the UKB Pharma Proteomics project, offers a glimpse into a future where early cancer detection and preventive intervention becomes a reality,” said Carl Raimond, President, Olink. “With continued research and development, discoveries such as these have the potential to transform how disease is diagnosed, treated, and prevented.” 

Related Links:
Olink Holding AB


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.